Deloitte’s 14th annual report on pharma innovation reveals a modest uptick in R&D returns for 2023, with the projected internal rate of return (IRR) for the pharma sector rising to 4.1% after hitting a low of 1.2% in 2022. Yet the report emphasizes the need for biopharma companies to adapt to ongoing challenges and leverage…